{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:07:56Z","timestamp":1792516076363,"version":"4.5.0"},"reference-count":67,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J of Med Genetics Pt C"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:italic>RET<\/jats:italic>\n                    gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular\u2010derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored. Selpercatinib and pralsetinib are selective RET inhibitors that have shown clear clinical benefits for patients in the LIBRETTO and ARROW trials, respectively. Currently, their development and application in clinical practice are ongoing. However, its efficacy in different\n                    <jats:italic>RET<\/jats:italic>\n                    pathogenic variants has not yet been well established. Although selpercatinib and pralsetinib achieved a high ORR, no data are available regarding the differences in tumor responses of both TC groups according to\n                    <jats:italic>RET<\/jats:italic>\n                    pathogenic variants. Clinical trials and literature have analyzed the efficacy of selective RET inhibitors with a special interest in the most common variants. A review of LIBRETTO and ARROW trials was made regarding the change in tumor size depending on the pathogenic variants. M918T pathogenic variant resulted in a higher complete response rate. Patients who underwent fusion had the highest ORR (objective response rate). MKi\u2010treated patients did not exhibit significant differences from untreated patients. Different\n                    <jats:italic>RET<\/jats:italic>\n                    pathogenic variants are not biomarkers of RETi response in TC. Selpercatinib showed a tendency to achieve a complete response. All patients with\n                    <jats:italic>RET<\/jats:italic>\n                    pathogenic variants should receive treatment with selpercatinib or pralsetinib at any moment of the therapeutic schedule owing to off\u2010target inhibition and toxicity. Therefore, new targets for drug sensitivity and resistance should be explored.\n                  <\/jats:p>","DOI":"10.1002\/ajmg.c.32127","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T06:15:10Z","timestamp":1735971310000},"page":"228-238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genomics Review of Selective\n                    <scp>RET<\/scp>\n                    Inhibitors Sensitivity in Thyroid Cancer Clinical Trials"],"prefix":"10.1002","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0199-6893","authenticated-orcid":false,"given":"Sara","family":"Gil\u2010Bernab\u00e9","sequence":"first","affiliation":[{"name":"Pathology Department, Faculty of Medicine Valladolid University  Valladoli Spain"},{"name":"Group Pathobiology of Cancer: Inter\u2010, Intra\u2010Tumor Heterogeneity and Molecular Targets Institute of Molecular Genetics and Biomedicine (IBGM)  Valladoli Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Garc\u00eda\u2010DeLaFuente","sequence":"additional","affiliation":[{"name":"Pathology Department, Faculty of Medicine Valladolid University  Valladoli Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garc\u00eda\u2010\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginesa","family":"Garc\u00eda\u2010Rost\u00e1n","sequence":"additional","affiliation":[{"name":"Pathology Department, Faculty of Medicine Valladolid University  Valladoli Spain"},{"name":"Group Pathobiology of Cancer: Inter\u2010, Intra\u2010Tumor Heterogeneity and Molecular Targets Institute of Molecular Genetics and Biomedicine (IBGM)  Valladoli Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Applied Pharmaceutical Science Inc.2023.\u201cA Phase 1 Study to Investigate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of APS03118 in Adult Patients With Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions.\u201dhttps:\/\/clinicaltrials.gov\/study\/NCT05653869."},{"key":"e_1_2_11_3_1","unstructured":"Boston Pharmaceuticals.2023.\u201cA Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non\u2010Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC).\u201dhttps:\/\/clinicaltrials.gov\/study\/NCT03780517."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)60421\u20109"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34493"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)30172\u20106"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010med\u2010061512\u2010105739"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.Supplement\u20101.49"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00011"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.09.030"},{"key":"e_1_2_11_13_1","unstructured":"COSMIC. n.d.\u201cCOSMIC \u2013 Catalogue of Somatic Mutations in Cancer.\u201dAccessed May 15 2024.https:\/\/cancer.sanger.ac.uk\/cosmic."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.021"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0477"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00393"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac325"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568\u2010023\u201000598\u2010y"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01861"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.141"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.08.040"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719"},{"key":"e_1_2_11_25_1","unstructured":"Helsinn Healthcare SA.2023.\u201cPhase I\/II Study of the Selective RET Inhibitor TAS0953\/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities.\u201dhttps:\/\/clinicaltrials.gov\/study\/NCT04683250."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032312"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041950"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0509"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC\u201022\u20100293"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0399"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11813"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128149"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE\u201012\u20100919"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC\u201018\u20100506"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.03.035"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016\u20103640"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010023\u201000630\u2010y"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg2538"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010018\u201002994\u20107"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32649"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC\u201023\u20100117"},{"key":"e_1_2_11_43_1","article-title":"RET Signaling Pathway and RET Inhibitors in Human Cancer. Front","volume":"12","author":"Regua A. T.","year":"2022","journal-title":"Oncologia"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC\u201012\u20100316"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE\u201010\u20100333"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010021\u201000470\u20109"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144951"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7824936"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3008"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy188"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698\u2010021\u201000188\u2010x"},{"key":"e_1_2_11_53_1","unstructured":"Shouyao Holdings (Beijing) Co. LTD.2023.\u201cA Phase I\/II Open\u2010Label Single\u2010Arm Study to Evaluate the Safety Tolerability Pharmacokinetics and Antineoplastic Activity of SY\u20105007 in Patients With RET\u2010Altered Advanced Solid Tumor.\u201dhttps:\/\/clinicaltrials.gov\/study\/NCT05278364."},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2010.223"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201018\u20100338"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698\u2010024\u201000563\u20104"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0363"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(21)00120\u20100"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.599"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy137"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201023\u20100467"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092\u20108674(85)90115\u20101"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1015"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00189"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113826"}],"container-title":["American Journal of Medical Genetics Part C: Seminars in Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajmg.c.32127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajmg.c.32127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajmg.c.32127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:59:44Z","timestamp":1779361184000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajmg.c.32127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/ajmg.c.32127"],"URL":"https:\/\/doi.org\/10.1002\/ajmg.c.32127","archive":["Portico"],"relation":{},"ISSN":["1552-4868","1552-4876"],"issn-type":[{"value":"1552-4868","type":"print"},{"value":"1552-4876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"2024-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}